The DOI matches its Crossref record; 262 of the 262 references it cites were found in a registry or an index.
Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Open accessAbstract
The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires an urgent deployment of advanced therapeutic options available. The role of nanotechnology is highly relevant to counter this "virus" nano enemy. Nano intervention is discussed in terms of designing effective nanocarriers to counter the conventional limitations of antiviral and biological therapeutics. This strategy directs the safe and effective delivery of available therapeutic options using engineered nanocarriers, blocking the initial interactions of viral spike glycoprotein with host cell surface receptors, and disruption of virion construction. Controlling and eliminating the spread and reoccurrence of this pandemic demands a safe and effective vaccine strategy. Nanocarriers have potential to design risk-free and effective immunization strategies for severe acute respiratory syndrome coronavirus 2 vaccine candidates such as protein constructs and nucleic acids. We discuss recent as well as ongoing nanotechnology-based therapeutic and prophylactic strategies to fight against this pandemic, outlining the key areas for nanoscientists to step in.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
WHO Declares COVID-19 a Pandemic.
Cucinotta, D., & Vanelli, M. (2020) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v91i1.9397 · Cited by 7,457
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
Rothan, H. A., & Byrareddy, S. N. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102433 · Cited by 5,840
Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676
Origin and evolution of pathogenic coronaviruses
Cui, J., Li, F., & Shi, Z.-L. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,515
Inflamm‐aging: An Evolutionary Perspective on Immunosenescence
FRANCESCHI, C., BONAFÈ, M., VALENSIN, S., OLIVIERI, F., DE LUCA, M., OTTAVIANI, E., & DE BENEDICTIS, G. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06651.x · Cited by 5,358
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020) · Science · doi:10.1126/science.abb2762 · Cited by 5,040
Guo (2020) · doi:10.1186/s40779-020-00240-0 · Cited by 4,735
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341 · cited 1×
“44 The binding a ffi nity of the RBD domain of SARS-CoV-2 and PD of ACE2 is higher when compared to SARS-CoV.”
ResultToll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,193
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008) · Nature Immunology · doi:10.1038/ni.1631 · Cited by 3,065
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
COVID-19 and the cardiovascular system
Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y., & Xie, X. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0360-5 · Cited by 2,970
Kidney disease is associated with in-hospital death of patients with COVID-19
Cheng, Y., Luo, R., Wang, K., Zhang, M., Wang, Z., Dong, L., Li, J., Yao, Y., Ge, S., & Xu, G. (2020) · Kidney International · doi:10.1016/j.kint.2020.03.005 · Cited by 2,941
Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020) · Science · doi:10.1126/science.abb3405 · Cited by 2,895
Evidence for gastrointestinal infection of SARS-CoV-2
Xiao, F., Tang, M., Zheng, X., Liu, Y., Li, X., & Shan, H. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.055 · Cited by 2,836
Nanoparticle-mediated cellular response is size-dependent
Jiang, W., Kim, B. Y. S., Rutka, J. T., & Chan, W. C. W. (2008) · Nature Nanotechnology · doi:10.1038/nnano.2008.30 · Cited by 2,776
Design and development of polymers for gene delivery
Pack, D. W., Hoffman, A. S., Pun, S., & Stayton, P. S. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1775 · Cited by 2,568
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., Li, X., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.008 · Cited by 2,330
Taking dendritic cells into medicine
Steinman, R. M., & Banchereau, J. (2007) · Nature · doi:10.1038/nature06175 · Cited by 2,127
The Architecture of SARS-CoV-2 Transcriptome
Kim, D., Lee, J.-Y., Yang, J.-S., Kim, J. W., Kim, V. N., & Chang, H. (2020) · Cell · doi:10.1016/j.cell.2020.04.011 · Cited by 2,123
Rational siRNA design for RNA interference
Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W. S., & Khvorova, A. (2004) · Nature Biotechnology · doi:10.1038/nbt936 · Cited by 2,094
Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor
Li, F., Li, W., Farzan, M., & Harrison, S. C. (2005) · Science · doi:10.1126/science.1116480 · Cited by 2,031
A Human Homolog of Angiotensin-converting Enzyme
Tipnis, S. R., Hooper, N. M., Hyde, R., Karran, E., Christie, G., & Turner, A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002615200 · Cited by 2,009
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Coronavirus infections and immune responses
Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., Pan, P., Wang, W., Hu, D., Liu, X., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25685 · Cited by 1,946
Autophagy in infection, inflammation and immunity
Deretic, V., Saitoh, T., & Akira, S. (2013) · Nature Reviews Immunology · doi:10.1038/nri3532 · Cited by 1,919
Liver injury in COVID-19: management and challenges
Zhang, C., Shi, L., & Wang, F.-S. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30057-1 · Cited by 1,906
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Coronaviruses post-SARS: update on replication and pathogenesis
Perlman, S., & Netland, J. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2147 · Cited by 1,764
The Molecular Biology of Coronaviruses
Masters, P. S. (2006) · Advances in Virus Research · doi:10.1016/s0065-3527(06)66005-3 · Cited by 1,761
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients
Liu, K., Chen, Y., Lin, R., & Han, K. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.005 · Cited by 1,642
Cross-presentation by dendritic cells
Joffre, O. P., Segura, E., Savina, A., & Amigorena, S. (2012) · Nature Reviews Immunology · doi:10.1038/nri3254 · Cited by 1,637
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
Zhou, Y., Hou, Y., Shen, J., Huang, Y., Martin, W., & Cheng, F. (2020) · Cell Discovery · doi:10.1038/s41421-020-0153-3 · Cited by 1,597
Developing Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic
(2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-200220-0772 · Cited by 1,537
Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems
Karimi, M., Ghasemi, A., Sahandi Zangabad, P., Rahighi, R., Moosavi Basri, S. M., Mirshekari, H., Amiri, M., Shafaei Pishabad, Z., Aslani, A., Bozorgomid, M., et al. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00798d · Cited by 1,519
Self-citationThe Global Macroeconomic Impacts of COVID-19: Seven Scenarios
McKibbin, W. J., & Fernando, R. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3547729 · Cited by 1,482
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., So, R. T. Y., Lv, H., Mok, C. K. P., & Wilson, I. A. (2020) · Science · doi:10.1126/science.abb7269 · Cited by 1,463
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
The SARS-CoV-2 outbreak: What we know
Wu, D., Wu, T., Liu, Q., & Yang, Z. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.03.004 · Cited by 1,431
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Dong, L., Hu, S., & Gao, J. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.01012 · Cited by 1,390
Multiple organ infection and the pathogenesis of SARS
Gu, J., Gong, E., Zhang, B., Zheng, J., Gao, Z., Zhong, Y., Zou, W., Zhan, J., Wang, S., Xie, Z., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050828 · Cited by 1,379
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O'Neil, C. P., Lee, L. K., Swartz, M. A., & Hubbell, J. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1332 · Cited by 1,350
Potential interventions for novel coronavirus in China: A systematic review
Zhang, L., & Liu, Y. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25707 · Cited by 1,348
Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China
Wu, J. T., Leung, K., Bushman, M., Kishore, N., Niehus, R., de Salazar, P. M., Cowling, B. J., Lipsitch, M., & Leung, G. M. (2020) · Nature Medicine · doi:10.1038/s41591-020-0822-7 · Cited by 1,311
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,297
The positive impact of lockdown in Wuhan on containing the COVID-19 outbreak in China
Lau, H., Khosrawipour, V., Kocbach, P., Mikolajczyk, A., Schubert, J., Bania, J., & Khosrawipour, T. (2020) · Journal of Travel Medicine · doi:10.1093/jtm/taaa037 · Cited by 1,294
From SARS to MERS, Thrusting Coronaviruses into the Spotlight
Song, Z., Xu, Y., Bao, L., Zhang, L., Yu, P., Qu, Y., Zhu, H., Zhao, W., Han, Y., & Qin, C. (2019) · Viruses · doi:10.3390/v11010059 · Cited by 1,265
Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1729069 · Cited by 1,252
van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,234
Danger signals: SOS to the immune system
Gallucci, S., & Matzinger, P. (2001) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00191-6 · Cited by 1,204
COVID-19: what is next for public health?
Heymann, D. L., & Shindo, N. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30374-3 · Cited by 1,138
SARS-CoV-2 Vaccines: Status Report
Amanat, F., & Krammer, F. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.007 · Cited by 1,120
Belouzard, S., Chu, V. C., & Whittaker, G. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809524106 · Cited by 1,073
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., Godeaux, O., Levin, M. J., McElhaney, J. E., Puig-Barberà, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603800 · Cited by 1,070
Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry
Simmons, G., Gosalia, D. N., Rennekamp, A. J., Reeves, J. D., Diamond, S. L., & Bates, P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505577102 · Cited by 1,052
Desforges, M., Le Coupanec, A., Dubeau, P., Bourgouin, A., Lajoie, L., Dubé, M., & Talbot, P. J. (2019) · Viruses · doi:10.3390/v12010014 · Cited by 1,048
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Ahn, D.-G., Shin, H.-J., Kim, M.-H., Lee, S., Kim, H.-S., Myoung, J., Kim, B.-T., & Kim, S.-J. (2020) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2003.03011 · Cited by 1,001
Regulation of Phagosome Maturation by Signals from Toll-Like Receptors
Blander, J. M., & Medzhitov, R. (2004) · Science · doi:10.1126/science.1096158 · Cited by 991
Programming the magnitude and persistence of antibody responses with innate immunity
Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Hua, T., Nakaya, H. I., Ravindran, R., Stewart, S., Alam, M., Kwissa, M., et al. (2011) · Nature · doi:10.1038/nature09737 · Cited by 975
Zhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C., & Middelberg, A. P. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.069 · Cited by 919
van Boheemen, S., de Graaf, M., Lauber, C., Bestebroer, T. M., Raj, V. S., Zaki, A. M., Osterhaus, A. D. M. E., Haagmans, B. L., Gorbalenya, A. E., Snijder, E. J., et al. (2012) · mBio · doi:10.1128/mbio.00473-12 · Cited by 914
Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis
Millet, J. K., & Whittaker, G. R. (2015) · Virus Research · doi:10.1016/j.virusres.2014.11.021 · Cited by 902
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies
Kanekiyo, M., Wei, C.-J., Yassine, H. M., McTamney, P. M., Boyington, J. C., Whittle, J. R. R., Rao, S. S., Kong, W.-P., Wang, L., & Nabel, G. J. (2013) · Nature · doi:10.1038/nature12202 · Cited by 885
Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function
Zervantonakis, I. K., Hughes-Alford, S. K., Charest, J. L., Condeelis, J. S., Gertler, F. B., & Kamm, R. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210182109 · Cited by 872
Báez-Santos, Y. M., St. John, S. E., & Mesecar, A. D. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2014.12.015 · Cited by 854
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
Jiang, S., Hillyer, C., & Du, L. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.007 · Cited by 847
A structural analysis of M protein in coronavirus assembly and morphology
Neuman, B. W., Kiss, G., Kunding, A. H., Bhella, D., Baksh, M. F., Connelly, S., Droese, B., Klaus, J. P., Makino, S., Sawicki, S. G., et al. (2011) · Journal of Structural Biology · doi:10.1016/j.jsb.2010.11.021 · Cited by 841
Song, W., Gui, M., Wang, X., & Xiang, Y. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007236 · Cited by 834
Liu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., Tang, H., Nishiura, K., Peng, J., Tan, Z., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123158 · Cited by 830
Fu, Y., Cheng, Y., & Wu, Y. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00207-4 · Cited by 788
Applications of nanotechnology for immunology
Smith, D. M., Simon, J. K., & Baker Jr, J. R. (2013) · Nature Reviews Immunology · doi:10.1038/nri3488 · Cited by 767
Synthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
Huang, P., Wang, D., Su, Y., Huang, W., Zhou, Y., Cui, D., Zhu, X., & Yan, D. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505212y · Cited by 716
Covid‐19 and the digestive system
Wong, S. H., Lui, R. N., & Sung, J. J. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15047 · Cited by 713
Cancer nanomedicine: from targeted delivery to combination therapy
Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 675
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
Yang, Z.-Y., Kong, W.-P., Huang, Y., Roberts, A., Murphy, B. R., Subbarao, K., & Nabel, G. J. (2004) · Nature · doi:10.1038/nature02463 · Cited by 665
Coronavirus Spike Proteins in Viral Entry and Pathogenesis
Gallagher, T. M., & Buchmeier, M. J. (2001) · Virology · doi:10.1006/viro.2000.0757 · Cited by 658
Niikura, K., Matsunaga, T., Suzuki, T., Kobayashi, S., Yamaguchi, H., Orba, Y., Kawaguchi, A., Hasegawa, H., Kajino, K., Ninomiya, T., et al. (2013) · ACS Nano · doi:10.1021/nn3057005 · Cited by 638
mRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624
New horizons in adjuvants for vaccine development
Reed, S. G., Bertholet, S., Coler, R. N., & Friede, M. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.09.006 · Cited by 618
Iwata-Yoshikawa, N., Okamura, T., Shimizu, Y., Hasegawa, H., Takeda, M., & Nagata, N. (2019) · Journal of Virology · doi:10.1128/jvi.01815-18 · Cited by 618
Application of Associative Neural Networks for Prediction of Lipophilicity in ALOGPS 2.1 Program
Tetko, I. V., & Tanchuk, V. Y. (2002) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci025515j · Cited by 617
Chan, J. F.-W., Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv392 · Cited by 608
In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight
Dahlman, J. E., Barnes, C., Khan, O. F., Thiriot, A., Jhunjunwala, S., Shaw, T. E., Xing, Y., Sager, H. B., Sahay, G., Speciner, L., et al. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.84 · Cited by 592
Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion
Walls, A. C., Xiong, X., Park, Y.-J., Tortorici, M. A., Snijder, J., Quispe, J., Cameroni, E., Gopal, R., Dai, M., Lanzavecchia, A., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.028 · Cited by 582
Tripathi, N. K., & Shrivastava, A. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00420 · Cited by 575
Kolishetti, N., Dhar, S., Valencia, P. M., Lin, L. Q., Karnik, R., Lippard, S. J., Langer, R., & Farokhzad, O. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011368107 · Cited by 565
Wong, R. S. M., Wu, A., To, K. F., Lee, N., Lam, C. W. K., Wong, C. K., Chan, P. K. S., Ng, M. H. L., Yu, L. M., Hui, D. S., et al. (2003) · BMJ · doi:10.1136/bmj.326.7403.1358 · Cited by 561
New horizons in adjuvants for vaccine development
Reed, S. G., Tomai, M., & Gale, M. J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.08.008 · Cited by 554
Sui, J., Li, W., Murakami, A., Tamin, A., Matthews, L. J., Wong, S. K., Moore, M. J., Tallarico, A. S. C., Olurinde, M., Choe, H., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307140101 · Cited by 550
Simmons, G., Reeves, J. D., Rennekamp, A. J., Amberg, S. M., Piefer, A. J., & Bates, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306446101 · Cited by 543
Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome
Sharp, F. A., Ruane, D., Claass, B., Creagh, E., Harris, J., Malyala, P., Singh, M., O'Hagan, D. T., Pétrilli, V., Tschopp, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804897106 · Cited by 540
Minagar, A., Shapshak, P., Fujimura, R., Ownby, R., Heyes, M., & Eisdorfer, C. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00207-1 · Cited by 537
ACE2: from vasopeptidase to SARS virus receptor
Turner, A. J., Hiscox, J. A., & Hooper, N. M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.04.001 · Cited by 517
Deng, Z. J., Morton, S. W., Ben-Akiva, E., Dreaden, E. C., Shopsowitz, K. E., & Hammond, P. T. (2013) · ACS Nano · doi:10.1021/nn4047925 · Cited by 516
Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy
Chen, Y., Zhu, X., Zhang, X., Liu, B., & Huang, L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.136 · Cited by 515
Nanoparticle Vaccines Against Infectious Diseases
Pati, R., Shevtsov, M., & Sonawane, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02224 · Cited by 514
The SARS-CoV-2 Vaccine Pipeline: an Overview
Chen, W.-H., Strych, U., Hotez, P. J., & Bottazzi, M. E. (2020) · Current Tropical Medicine Reports · doi:10.1007/s40475-020-00201-6 · Cited by 511
Yang, Z.-Y., Huang, Y., Ganesh, L., Leung, K., Kong, W.-P., Schwartz, O., Subbarao, K., & Nabel, G. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5642-5650.2004 · Cited by 490
COVID-19 and the liver: little cause for concern
Bangash, M. N., Patel, J., & Parekh, D. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30084-4 · Cited by 481
Nanoparticle Hydrophobicity Dictates Immune Response
Moyano, D. F., Goldsmith, M., Solfiell, D. J., Landesman-Milo, D., Miranda, O. R., Peer, D., & Rotello, V. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2108905 · Cited by 478
Detection of Microbial Infections Through Innate Immune Sensing of Nucleic Acids
Tan, X., Sun, L., Chen, J., & Chen, Z. J. (2018) · Annual Review of Microbiology · doi:10.1146/annurev-micro-102215-095605 · Cited by 443
Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
Maldonado, R. A., LaMothe, R. A., Ferrari, J. D., Zhang, A.-H., Rossi, R. J., Kolte, P. N., Griset, A. P., O’Neil, C., Altreuter, D. H., Browning, E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408686111 · Cited by 441
Accessory proteins of SARS-CoV and other coronaviruses
Liu, D. X., Fung, T. S., Chong, K. K.-L., Shukla, A., & Hilgenfeld, R. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.06.013 · Cited by 431
SARS-associated viral hepatitis caused by a novel coronavirus: Report of three cases
Chau, T.-N., Lee, K.-C., Yao, H., Tsang, T.-Y., Chow, T.-C., Yeung, Y.-C., Choi, K.-W., Tso, Y.-K., Lau, T., Lai, S.-T., et al. (2004) · Hepatology · doi:10.1002/hep.20111 · Cited by 424
Interferon-α2b Treatment for COVID-19
Zhou, Q., Chen, V., Shannon, C. P., Wei, X.-S., Xiang, X., Wang, X., Wang, Z.-H., Tebbutt, S. J., Kollmann, T. R., & Fish, E. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01061 · Cited by 417
Simmons, G., Zmora, P., Gierer, S., Heurich, A., & Pöhlmann, S. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.028 · Cited by 413
Molecular Interactions in the Assembly of Coronaviruses
de Haan, C. A. M., & Rottier, P. J. M. (2005) · Advances in Virus Research · doi:10.1016/s0065-3527(05)64006-7 · Cited by 408
Zhao, Z. (2003) · Journal of Medical Microbiology · doi:10.1099/jmm.0.05320-0 · Cited by 407
Sun, T.-M., Du, J.-Z., Yao, Y.-D., Mao, C.-Q., Dou, S., Huang, S.-Y., Zhang, P.-Z., Leong, K. W., Song, E.-W., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn103349h · Cited by 406
Li, X., Wang, L., Yan, S., Yang, F., Xiang, L., Zhu, J., Shen, B., & Gong, Z. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.03.053 · Cited by 402
Li, M., Chen, L., Zhang, J., Xiong, C., & Li, X. (2020) · PLOS ONE · doi:10.1371/journal.pone.0230295 · Cited by 401
Bridging Bio–Nano Science and Cancer Nanomedicine
Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b04855 · Cited by 382
Tetko, I. V., Tanchuk, V. Y., & Villa, A. E. P. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010368v · Cited by 381
Interferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory Syndrome: A Preliminary Study
Loutfy, M. R., Blatt, L. M., Siminovitch, K. A., Ward, S., Wolff, B., Lho, H., Pham, D. H., Deif, H., LaMere, E. A., Chang, M., et al. (2003) · JAMA · doi:10.1001/jama.290.24.3222 · Cited by 381
Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants
Hanson, M. C., Crespo, M. P., Abraham, W., Moynihan, K. D., Szeto, G. L., Chen, S. H., Melo, M. B., Mueller, S., & Irvine, D. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79915 · Cited by 381
Outbreak of a novel coronavirus
Du Toit, A. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0332-0 · Cited by 374
Nanoparticles for combination drug therapy
Ma, L., Kohli, M., & Smith, A. (2013) · ACS Nano · doi:10.1021/nn405674m · Cited by 367
Liao, L., Liu, J., Dreaden, E. C., Morton, S. W., Shopsowitz, K. E., Hammond, P. T., & Johnson, J. A. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502011g · Cited by 362
Prodrug-based nanoparticulate drug delivery strategies for cancer therapy
Luo, C., Sun, J., Sun, B., & He, Z. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.09.008 · Cited by 352
Tan, M. L., Choong, P. F. M., & Dass, C. R. (2010) · Peptides · doi:10.1016/j.peptides.2009.10.002 · Cited by 350
Li, H., Li, Y., Jiao, J., & Hu, H.-M. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.153 · Cited by 347
A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines
Brito, L. A., Chan, M., Shaw, C. A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G. R., Beard, C. W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.133 · Cited by 338
Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy
De Clercq, E., & Field, H. J. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706446 · Cited by 336
Polymer–Lipid Nanoparticles for Systemic Delivery of mRNA to the Lungs
Kaczmarek, J. C., Patel, A. K., Kauffman, K. J., Fenton, O. S., Webber, M. J., Heartlein, M. W., DeRosa, F., & Anderson, D. G. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608450 · Cited by 334
Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices
Tetko, I. V., Tanchuk, V. Y., Kasheva, T. N., & Villa, A. E. P. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000392t · Cited by 331
Bertram, S., Glowacka, I., Müller, M. A., Lavender, H., Gnirss, K., Nehlmeier, I., Niemeyer, D., He, Y., Simmons, G., Drosten, C., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05300-11 · Cited by 329
Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus
Łoczechin, A., Séron, K., Barras, A., Giovanelli, E., Belouzard, S., Chen, Y.-T., Metzler-Nolte, N., Boukherroub, R., Dubuisson, J., & Szunerits, S. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b15032 · Cited by 320
Sago, C. D., Lokugamage, M. P., Paunovska, K., Vanover, D. A., Monaco, C. M., Shah, N. N., Gamboa Castro, M., Anderson, S. E., Rudoltz, T. G., Lando, G. N., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811276115 · Cited by 313
Yeste, A., Nadeau, M., Burns, E. J., Weiner, H. L., & Quintana, F. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120611109 · Cited by 302
MERS-CoV spike protein: a key target for antivirals
Du, L., Yang, Y., Zhou, Y., Lu, L., Li, F., & Jiang, S. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1271415 · Cited by 301
Hunter, Z., McCarthy, D. P., Yap, W. T., Harp, C. T., Getts, D. R., Shea, L. D., & Miller, S. D. (2014) · ACS Nano · doi:10.1021/nn405033r · Cited by 301
Evaluation of candidate vaccine approaches for MERS-CoV
Wang, L., Shi, W., Joyce, M. G., Modjarrad, K., Zhang, Y., Leung, K., Lees, C. R., Zhou, T., Yassine, H. M., Kanekiyo, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms8712 · Cited by 299
Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations
Hamdy, S., Haddadi, A., Hung, R. W., & Lavasanifar, A. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.05.021 · Cited by 298
The potential chemical structure of anti‐SARS‐CoV‐2 RNA‐dependent RNA polymerase
Lung, J., Lin, Y., Yang, Y., Chou, Y., Shu, L., Cheng, Y., Liu, H. T., & Wu, C. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25761 · Cited by 295
Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy
Demento, S. L., Eisenbarth, S. C., Foellmer, H. G., Platt, C., Caplan, M. J., Mark Saltzman, W., Mellman, I., Ledizet, M., Fikrig, E., Flavell, R. A., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.034 · Cited by 290
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies
Zhu, Z., Chakraborti, S., He, Y., Roberts, A., Sheahan, T., Xiao, X., Hensley, L. E., Prabakaran, P., Rockx, B., Sidorov, I. A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701000104 · Cited by 287
Chen, C., Zhang, X., Ju, Z., & He, W. (2020) · PubMed · doi:10.3760/cma.j.cn501120-20200224-00088 · Cited by 277
Hamad, I., Al-Hanbali, O., Hunter, A. C., Rutt, K. J., Andresen, T. L., & Moghimi, S. M. (2010) · ACS Nano · doi:10.1021/nn101990a · Cited by 276
Hakim, F. T., Flomerfelt, F. A., Boyiadzis, M., & Gress, R. E. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.01.009 · Cited by 272
Tooze, J., Tooze, S. A., & Warren, G. (1984) · PubMed · Cited by 264
Coleman, C. M., Sisk, J. M., Mingo, R. M., Nelson, E. A., White, J. M., & Frieman, M. B. (2016) · Journal of Virology · doi:10.1128/jvi.01429-16 · Cited by 257
The Role of ACE2 in Cardiovascular Physiology
Oudit, G. Y., Crackower, M. A., Backx, P. H., & Penninger, J. M. (2003) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(02)00233-5 · Cited by 254
Mortola, E., & Roy, P. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.09.009 · Cited by 250
Zhang, Y., Li, N., Suh, H., & Irvine, D. J. (2018) · Nature Communications · doi:10.1038/s41467-017-02251-3 · Cited by 248
Arabi, Y. M., Shalhoub, S., Mandourah, Y., Al-Hameed, F., Al-Omari, A., Al Qasim, E., Jose, J., Alraddadi, B., Almotairi, A., Al Khatib, K., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz544 · Cited by 248
Prabakaran, P., Gan, J., Feng, Y., Zhu, Z., Choudhry, V., Xiao, X., Ji, X., & Dimitrov, D. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600697200 · Cited by 238
Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies
Pauletti, G. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00045-8 · Cited by 233
Nanoparticle-Mediated Systemic Delivery of siRNA for Treatment of Cancers and Viral Infections
Draz, M. S., Fang, B. A., Zhang, P., Hu, Z., Gu, S., Weng, K. C., Gray, J. W., & Chen, F. F. (2014) · Theranostics · doi:10.7150/thno.9404 · Cited by 231
Graham, R. L., Becker, M. M., Eckerle, L. D., Bolles, M., Denison, M. R., & Baric, R. S. (2012) · Nature Medicine · doi:10.1038/nm.2972 · Cited by 230
Rokni, M., Ghasemi, V., & Tavakoli, Z. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2107 · Cited by 219
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
Ashton, S., Song, Y. H., Nolan, J., Cadogan, E., Murray, J., Odedra, R., Foster, J., Hall, P. A., Low, S., Taylor, P., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad2355 · Cited by 218
Covid-19: India imposes lockdown for 21 days and cases rise
Pulla, P. (2020) · BMJ · doi:10.1136/bmj.m1251 · Cited by 209
Roadmap and strategy for overcoming infusion reactions to nanomedicines
Szebeni, J., Simberg, D., González-Fernández, Á., Barenholz, Y., & Dobrovolskaia, M. A. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0273-1 · Cited by 205
COVID-19 and emerging viral infections: The case for interferon lambda
Prokunina-Olsson, L., Alphonse, N., Dickenson, R. E., Durbin, J. E., Glenn, J. S., Hartmann, R., Kotenko, S. V., Lazear, H. M., O’Brien, T. R., Odendall, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200653 · Cited by 204
Hwang, W. C., Lin, Y., Santelli, E., Sui, J., Jaroszewski, L., Stec, B., Farzan, M., Marasco, W. A., & Liddington, R. C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603275200 · Cited by 203
Slütter, B., Bal, S., Keijzer, C., Mallants, R., Hagenaars, N., Que, I., Kaijzel, E., van Eden, W., Augustijns, P., Löwik, C., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.06.121 · Cited by 201
Getts, D. R., Turley, D. M., Smith, C. E., Harp, C. T., McCarthy, D., Feeney, E. M., Getts, M. T., Martin, A. J., Luo, X., Terry, R. L., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1004175 · Cited by 198
Peptide Targeted Lipid Nanoparticles for Anticancer Drug Delivery
Pearce, T. R., Shroff, K., & Kokkoli, E. (2012) · Advanced Materials · doi:10.1002/adma.201200832 · Cited by 192
Kim, U. J., Won, E.-J., Kee, S.-J., Jung, S.-I., & Jang, H.-C. (2016) · Antiviral Therapy · doi:10.3851/imp3002 · Cited by 192
Morton, S. W., Lee, M. J., Deng, Z. J., Dreaden, E. C., Siouve, E., Shopsowitz, K. E., Shah, N. J., Yaffe, M. B., & Hammond, P. T. (2014) · Science Signaling · doi:10.1126/scisignal.2005261 · Cited by 190
Li, A. V., Moon, J. J., Abraham, W., Suh, H., Elkhader, J., Seidman, M. A., Yen, M., Im, E.-J., Foley, M. H., Barouch, D. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006516 · Cited by 186
Surface engineering of nanoparticles for therapeutic applications
Kobayashi, K., Wei, J., Iida, R., Ijiro, K., & Niikura, K. (2014) · Polymer Journal · doi:10.1038/pj.2014.40 · Cited by 179
The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men
Kopetz, S., Lemos, R., & Powis, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2408 · Cited by 176
Lembo, D., Donalisio, M., Civra, A., Argenziano, M., & Cavalli, R. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1360863 · Cited by 174
Elshabrawy, H. A., Coughlin, M. M., Baker, S. C., & Prabhakar, B. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050366 · Cited by 172
Neurological Insights of COVID-19 Pandemic
Das, G., Mukherjee, N., & Ghosh, S. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00201 · Cited by 171
Bertholon, I., Vauthier, C., & Labarre, D. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0069-0 · Cited by 169
ACE2 expression and activity are enhanced during pregnancy
Levy, A., Yagil, Y., Bursztyn, M., Barkalifa, R., Scharf, S., & Yagil, C. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90592.2008 · Cited by 168
Gene-Directed Enzyme Prodrug Therapy
Zhang, J., Kale, V. M., & Chen, M. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9675-7 · Cited by 163
Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment
Nishimura, M., Jung, E.-J., Shah, M. Y., Lu, C., Spizzo, R., Shimizu, M., Han, H. D., Ivan, C., Rossi, S., Zhang, X., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0159 · Cited by 160
“Pathogen-Mimicking” Nanoparticles for Vaccine Delivery to Dendritic Cells
Elamanchili, P., Lutsiak, C. M. E., Hamdy, S. I., Diwan, M., & Samuel, J. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31802cf3e3 · Cited by 159
Cited by
Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 525
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
Pokrajac, L., Abbas, A., Chrzanowski, W., Dias, G. M., Eggleton, B. J., Maguire, S., Maine, E., Malloy, T., Nathwani, J., Nazar, L., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c10919 · Cited by 365
Towards safe and sustainable innovation in nanotechnology: State-of-play for smart nanomaterials
Gottardo, S., Mech, A., Drbohlavová, J., Małyska, A., Bøwadt, S., Riego Sintes, J., & Rauscher, H. (2021) · NanoImpact · doi:10.1016/j.impact.2021.100297 · Cited by 318
Theoretical basis for stabilizing messenger RNA through secondary structure design
Wayment-Steele, H. K., Kim, D. S., Choe, C. A., Nicol, J. J., Wellington-Oguri, R., Watkins, A. M., Sperberg, R. A. P., Huang, P.-S., Participants, E., & Das, R. (2020) · doi:10.1101/2020.08.22.262931 · Cited by 199
Metadata
- Authors
- Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-06-22
- Volume
- 14
- Issue
- 7
- Pages
- 7760-7782
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W3036620193
- Cited by
- 385
- References
- 262
- FWCI
- 9.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.